In a groundbreaking development for the healthcare AI sector, OpenEvidence, often dubbed the 'ChatGPT for doctors,' has achieved a staggering $12 billion valuation following a new funding round.
This Series D round, led by prominent investors Thrive Capital and DST Global, raised $250 million, doubling the company’s valuation in just three months, as reported by multiple sources.
The Rise of OpenEvidence in Healthcare AI
Based in Miami, OpenEvidence has emerged as a leader in providing AI-powered tools that assist U.S. physicians in searching clinical evidence and managing millions of consultations monthly.
The platform, which is free for clinicians and monetized through ads, has seen rapid adoption with reports indicating it now supports over 15 million consultations per month, a significant leap from earlier figures.
A History of Meteoric Growth
Founded to bridge the gap between complex medical data and actionable insights, OpenEvidence has consistently attracted major backers like Nvidia and Google Ventures since its earlier rounds.
Just months ago, in October 2025, the company was valued at $6 billion after a $200 million Series C round, showcasing its accelerated growth trajectory in the competitive AI landscape.
Impact on the Healthcare Industry
The success of OpenEvidence signals a transformative shift in healthcare, where AI tools are becoming indispensable for improving efficiency and decision-making among medical professionals.
With 40% of U.S. doctors reportedly using the platform, it is poised to redefine how clinical evidence is accessed and applied in real-time patient care.
Future Prospects and Challenges
Looking ahead, OpenEvidence aims to expand its capabilities, potentially integrating deeper AI functionalities to offer PhD-level evidence syntheses and personalized medical insights.
However, the company faces stiff competition from tech giants like OpenAI and Anthropic, who are also venturing into health information products, raising questions about market saturation.
Despite these challenges, investor confidence remains high, with industry analysts suggesting that an IPO could be on the horizon if growth metrics continue to impress.
For now, OpenEvidence stands as a beacon of innovation, proving that AI can heal not just funding gaps but also critical inefficiencies in healthcare delivery.
Andrew Lee
